SCHEMBL66901

SCHEMBL66901

c1cnc(-c2ncco2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGDS O60760 1/20 0.48
LTA4H P09960 1/20 0.42
BRD4 O60885 1/20 0.37
ADORA2A P29274 3/20 0.36
ADORA1 P30542 3/20 0.36
PIN1 Q13526 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
GLRA3 O75311 1/20 0.33
GLRB P48167 1/20 0.33
CYP19A1 P11511 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CSNK1D P48730 1/20 0.32
CSNK1E P49674 1/20 0.32
HDAC4 P56524 1/20 0.32
ADRA1A P35348 3/20 0.31
ADRA2A P08913 2/20 0.31
ADRA1D P25100 2/20 0.31
ADRA1B P35368 1/20 0.31
NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882183 0.80 HPGDS (0.41) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL100765 0.80 HPGDS (0.46) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL17701262 0.78 HPGDS (0.40) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL15627195 0.77 SMN1; SMN2 (0.41) HPGDSLTA4HADORA2AADORA1KDM4E
SCHEMBL13114685 0.77 HPGDS (0.47) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL17701187 0.73 HPGDS (0.37) HPGDSLTA4H
SCHEMBL8363957 0.73 HPGDS (0.41) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL30066184 0.73 HPGDS (0.41) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL27176352 0.73 HPGDS (0.41) HPGDSLTA4HBRD4ADORA2AADORA1
SCHEMBL15629752 0.72 SMN1; SMN2 (0.41) HPGDSLTA4HKDM4ENPC1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101959884-A 6-heterocyclic imidazo [1, 2-alpha ] pyridine-2-carboxamide derivatives, preparation and therapeutic use thereof SANOFI AVENTIS 2011-01-26 CN claimed
CN-101553233-A Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-10-07 CN claimed
CN-101553232-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-10-07 CN claimed
CN-101516379-A Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS LLC (US) 2009-08-26 CN claimed
CN-1222527-C Pyridine and pyrimidine derivatives and their use as inhibitors of cytokines mediating diseases ASTRAZENECA AB (SE) 2005-10-12 CN claimed
CN-1660849-A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokines mediating diseases ASTRAZENECA AB (SE) 2005-08-31 CN claimed
CN-1351604-A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokines mediating diseases ASTRAZENECA AB (SE) 2002-05-29 CN claimed
US-20250289818-A1 HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER TOLREMO THERAPEUTICS AG (CH) 2025-09-18 US disclosed
CN-116867373-A Herbicidal composition 日本曹达株式会社 2023-10-10 CN disclosed
US-20230067929-A1 HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER TOLREMO THERAPEUTICS AG (CH) 2023-03-02 US disclosed
CN-109561684-A The pyrimidine compound of weeding 巴斯夫欧洲公司 2019-04-02 CN disclosed
US-9812315-B2 Treating solution for electronic parts, and process for producing electronic parts FINE POLYMERS CORPORATION (JP) 2017-11-07 US disclosed
US-20150279654-A1 TREATING SOLUTION FOR ELECTRONIC PARTS, AND PROCESS FOR PRODUCING ELECTRONIC PARTS FINE POLYMERS CORPORATION (JP) 2015-10-01 US disclosed
CN-1360582-A Quinazoline derivs. ASTRAZENECA UK LTD (GB) 2002-07-24 CN disclosed
CN-1351604-A Pyridine and pyrimidine derivatives and their use as inhibitors of cytokines mediating diseases ASTRAZENECA AB (SE) 2002-05-29 CN disclosed
CN-1082503-C Process for the preparation of methylamides of alpha-methoxyiminocarboxylic acids and intermediates therefor BASF AG (DE) 2002-04-10 CN disclosed
CN-1272109-A Method for producing isoxazolidinedione compound JAPAN TOBACCO INC (JP) 2000-11-01 CN disclosed
CN-1233241-A Propionic acid derivatives and uses thereof JAPAN TOBACCO INC (JP) 1999-10-27 CN disclosed
CN-1200117-A Phenylacetic acids, processes for their preparation and agents containing them BASF AG (DE) 1998-11-25 CN disclosed
CN-1153509-A Process for the preparation of methylamides of alpha-methoxyiminocarboxylic acids and intermediates therefor BASF AG (DE) 1997-07-02 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289818-A1 HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER SLC10A1, SLC6A6, SLC10A6 HPGDS 1558/4885LTA4H 2010/4885BRD4 3981/4885
US-20230067929-A1 HETEROCYCLIC DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF CANCER SLC10A1, SLC6A6, SLC10A6 HPGDS 2109/4885LTA4H 2419/4885BRD4 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.